Ainos to initiate study of new potential VELDONA-based drug

Ainos announced the initiation of a clinical study for a new potential VELDONA-based drug for pet disease. The study is aimed at evaluating the clinical efficacy of low-dose oral interferons in treating feline chronic gingivostomatitis, a serious and chronic painful oral disease characterized by inflammation or abnormal proliferation in the oral cavity. This marks another meaningful step in the Company’s strategy for expanding its product line into the global pet care market, which follows the Memorandum of Understanding Ainos signed last year with SIDSCO Biomedical Co., Ltd. The clinical trials are expected to run for approximately ten months from May 24, 2024 to March 31, 2025.